BAMBUTEROL

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C18H29N3O5
Molecular Weight	367.4407
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(C)NCC(c1cc(cc(c1)OC(=O)N(C)C)OC(=O)N(C)C)O

InChI

InChIKey=ANZXOIAKUNOVQU-UHFFFAOYSA-N

InChI=1S/C18H29N3O5/c1-18(2,3)19-11-15(22)12-8-13(25-16(23)20(4)5)10-14(9-12)26-17(24)21(6)7/h8-10,15,19,22H,11H2,1-7H3

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24277179
Curator's Comment:: https://www.medicines.org.uk/emc/medicine/9574 | http://www.meppo.com/pdf/drugs/2596-BAMBEC-ORAL-SOLUTION-1427211370.pdf | https://www.ncbi.nlm.nih.gov/pubmed/2906603

Bambuterol is a remarkably selective and potent inhibitor of cholinesterase. BAMBEC (Bambuterol hydrochloride) oral solution or tablets are indicated for the management of asthma, bronchospasm and/or reversible airways obstruction.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Beta-2 adrenergic receptor 197 Target ID: CHEMBL210 Sources: https://www.medicines.org.uk/emc/medicine/9574	Agonist 2456	Asthma Chronic obstructive pulmonary disease
Butyrylcholinesterase 36 Target ID: CHEMBL1914 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2906603 \| https://www.ncbi.nlm.nih.gov/pubmed/25504505	Inhibitor 7701		17 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic obstructive pulmonary disease 174 Sources: https://www.medicines.org.uk/emc/medicine/9574 http://www.meppo.com/pdf/drugs/2596-BAMBEC-ORAL-SOLUTION-1427211370.pdf	Primary	Beta-2 adrenergic receptor	Approved 7997	BAMBEC Approved Use BAMBEC (Bambuterol hydrochloride) oral solution or tablets are indicated for the management of asthma, bronchospasm and/or reversible airways obstruction.
Asthma 226 Sources: https://www.medicines.org.uk/emc/medicine/9574 http://www.meppo.com/pdf/drugs/2596-BAMBEC-ORAL-SOLUTION-1427211370.pdf	Primary	Beta-2 adrenergic receptor	Approved 7997	BAMBEC Approved Use BAMBEC (Bambuterol hydrochloride) oral solution or tablets are indicated for the management of asthma, bronchospasm and/or reversible airways obstruction.

PubMed

Title	Date	PubMed
Tremor in healthy volunteers after bambuterol and terbutaline CR-tablets.	1993	8299660
Bambuterol and terbutaline in human cerebrospinal fluid and plasma.	1993	8223836
Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists.	1998 Jul	9797754

Patents

Sample Use Guides

In Vivo Use Guide

BAMBEC (Bambuterol hydrochloride) Tablets 10 mg. The recommended starting doses are 10 mg–20 mg. The 10 mg dose may be increased to 20 mg if necessary after 1–2 weeks, depending on the clinical effect. In patients who have previously tolerated beta2-agonists well, the recommended starting dose, as well as maintenance dose, is 20 mg.

Route of Administration: Oral

Name

Type

Language

BAMBUTEROL

Official Name

English

BAMBUTEROL [INN]

Common Name

English

BAMBUTEROL [WHO-DD]

Common Name

English

(+/-)-5-(2-(TERT-BUTYLAMINO)-1-HYDROXYETHYL)-M-PHENYLENE BIS(DIMETHYLCARBAMATE)

Systematic Name

English

BAMBUTEROL [MI]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QR03CC12